Dimensional Fund Advisors
RAPP

Dimensional Fund Advisors’s Rapport Therapeutics RAPP Stock Holding History

Dimensional Fund Advisors’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.02M Buy
224,498
+141,011
+169% +$3.97M ﹤0.01% 2388
2025
Q4 		$2.53M Buy
83,487
+72,157
+637% +$2M ﹤0.01% 2687
2025
Q3 		$337K Buy
+11,330
New +$202K ﹤0.01% 3056

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Dimensional Fund Advisors's RAPP Position: Q1 2026 in Review

Dimensional Fund Advisors increased its Rapport Therapeutics (RAPP) stake by 169% in Q1 2026, buying an estimated $3.97M and bringing the position to 224,498 shares worth $7.02M. The position accounts for ﹤0.01% of the portfolio, ranked #2388.

Dimensional Fund Advisors first reported a position in RAPP in Q3 2025 and has held it in 3 quarters since. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Dimensional Fund Advisors held 224,498 shares of Rapport Therapeutics worth $7.02M as of Q1 2026.
  • Dimensional Fund Advisors bought 141,011 Rapport Therapeutics shares in Q1 2026, an estimated $3.97M.
  • Rapport Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q1 2026, its #2388 holding.
  • Dimensional Fund Advisors first reported a position in Rapport Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.